Galapagos

Generaal De Wittelaan L 11A3

2800 Mechelen

BE

Galapagos

Foundation date

30/06/1999

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    13 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022